论文部分内容阅读
糖尿病肾病(DN)的早期临床证据是微量白蛋白尿,然而,当一些患者出现微量尿白蛋白(UAlb)时,其肾脏组织已发生明显的病理改变。当患者出现临床白蛋白尿后,其肾小球滤过率(GFR)将以每年101%的速度下降。本文就蛋白质组学技术在DN发病机制及生物学标志研究中的应用作一综述。一、蛋白质组学技术蛋白质组学技术包括样品制备、蛋白质的分离、鉴定技术和生物信息学,其核心是分离和鉴定技术。蛋白质分离技术主要是二维聚丙烯酰胺凝胶电泳(2DE),用于简化蛋白质
Early clinical evidence of diabetic nephropathy (DN) is microalbuminuria, however, when some patients develop microalbuminuria (UAlb), significant renal pathological changes have taken place. When patients develop clinical albuminuria, their glomerular filtration rate (GFR) will decrease at a rate of 101% per year. This review summarizes the applications of proteomics in the study of the pathogenesis and biological markers of DN. First, the proteomics technology Proteomics techniques include sample preparation, protein separation, identification and bioinformatics, the core is the separation and identification techniques. Protein separation technology is mainly two-dimensional polyacrylamide gel electrophoresis (2DE), used to simplify the protein